Audi, SAIC Launch China Innovation Hub for New AUDI Models 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
France Targets Shein, Temu With Fast-Fashion Fees 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
OpenAI Rejects Apple Trade Secret Theft Claims 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Add as a preferred source on Google
MENLO PARK, Calif., March 19, 2018 -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 3:30 PM EDT.
A live audio webcast of Corium’s presentation may be accessed here or by visiting “Events & Presentations” in the Investors section of the Company’s website at www.coriumintl.com. The webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumintl.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Investor and Media Contact:
SMP Communications
Susan M. Pietropaolo
[email protected]
(201) 923-2049
Source: Corium
